Navigation Links
Maven Biotechnologies Receives $1.96 Million From the National Institutes of Health (NIH) to Develop Their LFIRE™ Label-Free Detection Technology for Proteomics

PASADENA, Calif., Oct. 1 /PRNewswire/ -- Maven Biotechnologies today announced that the company has been awarded $1.96 million by the National Institute for Allergy and Infectious Disease (NIAID), part of the NIH, to support the commercialization of their LFIRETM imaging technology for label-free protein microarrays and cell-based assays. The highly competitive grant was awarded to Maven through the federal stimulus package initiative for Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies (BRDG-SPAN).



"Maven welcomes the support of the NIH to bring our platform to market," says Chief Technology Officer David Ralin. "LFIRETM's label-free, multiplexed capabilities and inherent simplicity will directly benefit our customers, delivering better results in less time and with lower costs." Target applications for the technology include - but are not limited to - immunoassays in the research and diagnostics markets, cell-based studies, high-throughput pharmaceuticals screening and the established label-free applications in biomolecular interaction analysis.

Chief Engineering Officer Jeffrey Chongsathien M.A. Cantab. adds, "We look forward to creating a robust, flexible and modular product portfolio of laboratory instrumentation and consumables, built on LFIRETM." The initial instrument will be a desktop microplate reader, with a set of 'alpha' evaluation units expected to be completed in the first quarter of 2011 and made available for use by key academic collaborators and strategic industry partners.

Company Founder and CEO William Rassman M.D. noted that the grant will 'jump-start' the commercialization of the product and will be the forerunner of other funding events.

About Maven Biotechnologies

Maven Biotechnologies ( is a privately-held biotechnology company located in Pasadena, CA. The company has developed LFIRE™ [pronounced: el - fire] - a flexible, cost-effective, high density imaging technology for the multiplexed, quantitative, label-free, real-time characterization of biomarker binding reactions. The platform addresses applications in biomedical research, drug discovery, immunodiagnostics, biodefense, biological manufacturing and point-of-care. Maven holds 14 granted US and international patents.

SOURCE Maven Biotechnologies
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU)
2. PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy
3. PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
4. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
5. Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies
6. TriLink BioTechnologies to Sponsor Take Me Out to the Ballgame, a SAY San Diego Event Benefiting San Diego Families in Need
7. Novel Stem Cell Therapy From Cellonis Biotechnologies Can Help Children With Diabetes Get Back Their Normal Lives
8. Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies
9. TriLink BioTechnologies, Inc. Launches New Website and OligoBuilder(R)
10. IMBiotechnologies Receives FDA Clearance to Market Occlusin(R) 500 Biodegradable Microspheres in the U.S.
11. Epeius Biotechnologies Reports Major Clinical Advances: Noteworthy Clinical Case Studies in Cancer Gene Therapy
Post Your Comments:
(Date:6/27/2016)... ON , June 27, 2016 /PRNewswire/ - BIOREM Inc. ... has been advised by its major shareholders, Clean Technology ... United States based venture capital ... shares of Biorem (on a fully diluted, as converted ... the disposition of their entire equity holdings in Biorem ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, former ... of the University of North Carolina Kenan-Flagler Business School effective June ... UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes and ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
Breaking Biology Technology:
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
Breaking Biology News(10 mins):